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A b stra c t—Dimethylaminopropiophenone is reduced (40 %) and ex- 
creted (25 %) unchanged in fairly equal amounts and to a small extent 
demethylated. Diethylaminopropiophenone is mainly reduced (20 %) 
and dealkylated (25 %). The dealkylated product ethylaminopropio- 
phenone is mainly excreted unchanged (40 %) and also the diethyl- 
norephedrine formed is mainly excreted unchanged and for a small 
part dealkylated to ethylnorephedrine.
Diethylaminopropiophenone has no big excretion of the unaltered 
compound (2 %). The reduction of the tertiary amines is much more 
pronounced than that of the secondary ones. The tertiary amino­
propiophenones are rapidly dealkylated to the secondary ones and this 
behaviour is in accordance with the rate of dealkylation of tertiary 
amphetamines.
The metabolism of aminopropiophenones shows 4 competitive pathways for 
eliminating the compound from the body. The metabolic routes that take 
place are parahydroxylation, reduction, deamination, dealkylation, but also 
there is excretion of the unchanged compound and the metabolites by the 
kidneys.
Schreiber (1) produced evidence for all these reactions in the metabolism of 
diethylaminopropiophenone, but stated also that the parahydroxylation is a 
minor pathway. Beckett (2, 3) examined the excretion of 4-chIoroethylamino- 
propiophenone and its metabolites and found that the total amount excreted 
of non-acid compounds was about 50 %. When examining the N-alkylsubstitu- 
ted aminopropiophenones and their metabolites excreted into the urine, it is 
observed that all the compounds show a particular metabolic behaviour.
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Aminopropiophenone is partly reduced to norephedrine (32 %). T] 
ephedrine formed is excreted mainly due to its low lipid solubility (4 
N-methylaminopropiophenone is mainly demethylated to aminoproj 
none (60 %). Ethylaminopropiophenone is excreted mainly unchanged i 
urine (45 %) and there is little dealkylation and reduction.
Isopropylaminopropiophenone is mainly excreted into the urine uncl 
but the rapid decrease of the compound from the body resembled th  
elimination of isopropylamphetamine (5).
The compounds N-ethyl, N-propyl, N-isopropyl and N-butylaminoj 
phenone all have nearly the same pK& value (Table I) and lipid solubili 
this may be the most important factor in the metabolism and renal ex 
competition.
T a b l e  I
pKa values, apparent and true partition coefficients of some N-alkyl substituted
propiophenones
Compound pK.a TPChept TPCcM APChept AP
Aminopropiophenone 8.16
N-methylamino etc... 7.59 0.22 keto 48
0.10 enol 20
N-ethyl etc... 8.40 0.500 214 0.05 15
N-propyl etc... 8.46 27.4 2750 2.25 22;
N-isopropyl etc... 8.45 28.2 3050 2.25 24'
N-butyl etc... 8.47 157 15400 12.2 120(
N-dimethyl etc... 8.09 4.60 40.5 0.78 (
N-diethyl etc... 8.78 525 15000 21 60(
APChept is the apparent partition coëfficiënt at pH 7.40 in the system heptan 
(Teorell buffer).
TPCcj,i is the true partition coëfficiënt in the system chloroform/water.
Dimethylaminopropiophenone is reduced (40 %) and excreted (25 
changed in fairly equal amounts and to a small extent demethylated (F
Dimethylnorephedrine also is slightly demethylated to methylnoreph 
and mainly excreted unchanged (6).
Diethylaminopropiophenone is mainly reduced (20 %) and dealk 
(25 %). The dealkylated product ethylaminopropiophenone is mainly ex 
unchanged (40 %) and also the diethylnorephedrine formed is mainly ex 
unchanged and for a small part dealkylated to ethylnorephedrine.
Diethylaminopropiophenone has no big excretion of the unaltered com] 
(2 %). This can be explained by its high lipid solubility and the compar;
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cumulative rena!
F ig. i
Renal excretion rate, urine pH, urine production and cumulative renal excretion of
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The observed quantitative difference in the way of metabolism of : 
propiophenones compared to that of amphetamines can be explained as f< 
For the deamination and dealkylation a H atom is needed (7) and 1 
atom is directly involved in the rate limiting step of this oxydative dearni; 
When the H atom is not available, as with phentermine, the oxydative r( 
is blccked, and the ccmpound is excreted unchanged in the urine for ] 
Aminopropiophenones show a keto-enol tautomerism. This means tha 
certain fraction of the total amount of aminopropiophenone present 
liver or metabolic site of the enzyme, the required H atom is present 
mination occurs to a much smaller amount than with amphetamines. Inc: 
the substituent in N-aminopropiophenone did not show an increase ii 
kylation as observed with the dextro isomers of N-alkylsubstituted air: 
mines. It was observed with the dealkylation of dextro and levo N-alkyl 
tuted amphetamines that the key for the reaction is the steric configura 
the hydrogen atom of the amphetamine moiety.
With analogy to this observation it may be understandable that th< 
of the size and nature of the substituents at the nitrogen atom of ami 
piophenones is less pronounced.
In the keto-enol tautomerism, the enol form of the aminopropiophen 
excreted unchanged into the urine, or conjugated and then excreted. Tl 
form can be deaminated and dealkylated.
With the combined gaschromatograph-mass spectrometer LKB 9000 
observed that the KOH of the column 20 % Apiezon-5 % KOH ca 
dehydrogenation of the secondary aminopropiophenones. The structu 
be a linear one. The tertiary amines, diethyl- and dimethylaminopropiop 
were not dehydrogenated, and therefore it must be assumed that the st 
is more a cyclic one. The reduction of the tertiary amines is much mo 
nounced than that of the secondary ones. The tertiary aminopropiopl 
are rapidly dealkylated to the secondary ones and this behaviour is in acci 
with the rate of dealkylation of tertiary amphetamines.
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Psychopharmacology of Amphetamines
J. M. VAN ROSSUM
Department ofPharmacology, Catholic University o f Nijmegen, Nijmegen (The Netherlands)
Amphetamine is a prototype of the psychomotor-stimulant drugs or “wekamines”. 
Alertness, stimulation of loco-motoractivity, suppression of fatigue and sleepiness 
are typical for the central stimulating effects of amphetamine and a number of related 
compounds.
Ephedrine, the active principle of Ephedra vulgaris (2) and cathine or nor-pseudo 
ephedrine from the leaves of Catha edülis (7) are the oldest known naturally occurring 
amphetamine derivatives with psychomotor stimulant action. Cocaine from Erythro- 
xylon coca (7), although structurally not related to amphetamine (Fig. 1) is a psycho­
motor stimulant drug, very much so like amphetamine and methamphetamine.
Methamphetamine, the iV-methyl analogue of dextro rotatory amphetamine, has 
been synthetized long before amphetamine and it is still the most potent psychomotor 
stimulant drug at present available.
INTRODU CTION
cocaine [ - )  2 R ;3 S
e p h e d r in e  |- ) ,1 R ;2 S  
OH
hyoscyam ine 3 a ; 1' S a m p h e ta m in e  (+ ) 2 S
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DIFFERENT COMPONENTS IN THE CENTRAL STIMULANT ACTION OF AMPHI
Cocaine and cathine were the first drugs used for the suppression of 
appetite. Toxic side-effects as the induction of paranoid psychotic stat' 
described for cocaine almost a century ago (6). The first clinical applic 
phetamine was in the treatment of narcolepsy (8). Amphetamine-like dru 
used also in cases of depression, Parkinson’s disease, hyperkinesia in ch 
elderly mentally retarded patients. lts therapeutic success is at the best 
for the treatment of narcolepsy and adipositas.
On the other hand, the non-medical use of amphetamine both with resp 
by athletes, cyclists etc. and drug-abuse by addicts has increased tremend 
the last decade. In case of doping suppression ot fatigue is the desired e 
addicts the euphoria is aimed at, leading to a perversion of the rewarc 
system in the brain. Because of the high doses (especially i.v.) used, a p 
chosis is often experienced together with an excess of stereotyped behavi 
grinding, ticks etc.
Good evidence is available that the appetite suppression brought abou 
amine is unrelated to its typical psychomotor stimulant effects. There ar 
in this group that are purely stimulant (e.g. pemoline), mainly stimulant I 
doses appetite reducing (e.g. methamphetamine, phenmetrazine), stimi 
as appetite suppressive in the same doses (e.g. amphetamine), mainly su] 
in larger doses stimulating (e.g. amfepramon) and finally merely appetiti 
(e.g. chlorphentermine and fenfluramine) (16).
Also the various other components of the amphetamine action as fati 
sion, awakening effects, motor-stimulant actions, euphoric effects, psyc) 
and stereotyped behavioural effects are not necessarily connected. In 
vatives one component may be more pronounced than in another.
In addition the various amphetamines also differ in a pharmacokinetii 
implies that the various amphetamine derivatives may differ with respec 
of absorption, the rate of elimination and the rate of penetration into \ 
in the brain. As a result certain amphetamines may produce strong eup 
because they reach the brain very rapidly, while for other drugs in t 
euphoric effects may almost be absent.
Obviously the way of application is very important for the effects that £ 
administration of various amphetamine-like drugs. Following intravem 
tration, the concentration in the blood is initially very high and if such 
penetrate into the brain rapidly also a very large concentration in the brai 
As a consequence such a compound may produce very intensive but
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C T r  c r r " " ‘ C T r * -  C T Ü X
dexamphetamine 
|+) 2S, Dexedrine8
methamphetamine 
(+) 2S ; PervitinR
dimethamphetamine 
l+!2S MetrotoninR naphtyridine
alfetamine
AletamineR
cypenamine dextrofemine 
f+1 2S
tetrahydronapbtylamine
phenmetrazine tencamtamine 
ReactivanR
/
C C C c _ c
zytof uramine 
( + ]  th re o  2 S ; 3 S
p h e n y le th y  Lamine
C^ = 0
o ^ ö  0 ^ 0
facetopera'n 
- )  threo 1S; 2 S 
LidepranR
methylfemdate 
Ritalin H 
M threo 1R;2R
benzphetamine
DidrexR
pemoline
TradonR
&
pyrovalerone
CentrotonR
*  also in use as anorectic drug
*  *  to be considered as a dangerous addictive drug
Prolintane 
CatovitR
Fig. 2.
N - C - C
ethylamphetamine
Apetinil*
ST RU CTURE-ACH VIT Y RELATIONSfflP
The phenylethylamine moiety seems to be essential for the psychomotor-stimulant 
action of amphetamine derivatives (19). Phenylethylamine as such is a weak psycho- 
motor stimulant because it is rapidly metabolised whereas after blockade of bio-
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active (18). On the other hand various groups may be attached to the 
side-chain in the amphetamine derivatives, without losing too much act;
As pointed out before, we have, however, to realise that the various 
in the action of amphetamine are not represented quantitatively to the 
in the various derivatives. This means that in structure activity relations 
to consider a particular effect, and not in the one study one effect and 
case another effect, and still in other cases a mixture of the various actio 
a number of well-known amphetamine-like compounds have been presi 
this table it may be seen that these compounds are structurally related. i 
pounds except a few are phenylethylamine derivatives.
As pointed out in the i n t r o d u c t io n  cocaine belongs also to the p; 
stimulant drugs, although the chemical structure of cocaine is complel 
from those of the amphetamines and their derivatives. In addition thej 
synthetic compounds like pemoline and NCA (naphtyridine), which art 
acidic substances, while the amphetamine-like compounds have basic nai 
It is therefore likely that the mechanism of central stimulant action c 
compounds may differ from those of amphetamine and methamphetam 
be remarked here, that the mechanism of action of cocaine also differs 1 
amphetamine. It has long been known that the cocaine action is abolishec 
pretreated with reserpine, while the action of amphetamine is not abc 
Some investigators find an increase of the effect of amphetamine followi 
treatment, others find no change while still others note a decrease. Furtl 
change in the action of amphetamine is dose-dependent (11, 13). At cl 
vation, it appears that the so-called “over-all” activity of amphetamine 
changed by pretreatment with reserpine, but that certain components ii 
are augmented while others are reduced. The reserpine treatment theref 
the various components in the action of amphetamine. It is therefore 
certain amphetamine-derivatives may be blocked completely by reserpin 
compounds particular components in the action are pronounced.
Not only amphetamine-like drugs may differ considerably in chemic 
and nevertheless produce a similar central stimulant action (although 
components in this effect may be quantitatively and qualitatively differem 
closely related amphetamine-like compounds may have central stimulant 
others may not. For instance it is known that there is a considerable di 
tween the central stimulant action of dextro-methamphetamine and levo-n 
amine. This effect is even more pronounced in isopropylamphetamine. 
propylamphetamine is a central stimulant while levo-isopropylamphet; 
central stimulant action and rather induces fatigue.
TT+ i f  ■««+ n t  r*11 +1 ------- --- !_ _Z---- 1‘t 1 t •
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body into secondary and primary nitrogen containing compounds. So if benzphet- 
amine is dealkylated by removal of the benzyl group, methamphetamine is formed. 
This process of biotransformation occurs slowly, so that after administration of 
benzphetamine, a slow continuous production of methamphetamine occurs, whereby 
long-lasting low levels of methamphetamine are produced in the body. If the bio­
transformation is further retarded, but not yet completely blocked, the production 
of methamphetamine is further retarded and the effect produced by benzphetamine 
is extremely long-lasting. Complete blockade of biotransformation, however, abolishes 
the central effects of benzphetamine. This is so because benzphetamine itself is hardly 
at all excreted in the urine, while amphetamine and methamphetamine are reasonable 
well excreted (20). Therefore, benzphetamine itself does leave the body as such but 
its main route of elimination is dealkylation to methamphetamine and eventually 
amphetamine. From these data it may be concluded that benzphetamine when injected 
directly into the blood would not cause a central stimulation but it will take some 
time until sufficiënt methamphetamine is formed. So although methamphetamine 
is a dangerous addictive compound the drug benzphetamine, from which methamph­
etamine can be formed, may not necessarily or probably not at all be addictive.
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BRAIN MONOAMINES AND AMPHETAMINE ACTION
Reserpine blocks certain amphetamine actions and completely blocks t 
certain amphetamine-like compounds (Fig. 3) (7a). In this figure a rhesu 
injected with amphetamine resulting in a staring attitude. Reserpine eau 
known inactivation without severe sedation. In the reserpinized monkey ai 
seems to induce hallucinatory effects which have a “paranoid” character. I 
known that reserpine has profound influences on brain monoamines. I 
the level of noradrenaline and 5-hydroxytryptamine but also on the le 
amine. As pointed out before, the effect of cocaine is blocked by n 
reserpinized animals in which cocaine is ineffective, the cocaine effect 
stored by giving these animals a low dose of L-Dopa. Administration of E 
of dioxyphenyl serine from which directly noradrenaline may be fo 
5-hydroxytryptophane from which 5-HT will be formed are not effective 
the action of cocaine in reserpinized animals. From such experiments it 
likely that dopamine is of predominant importance for the action of c< 
the effects of amphetamine in reserpinized rats in which especially ster 
haviour is pronounced but in which also a typical social interaction occ 
pendent on dopamine. In normal rats a low dose of dexamphetamine 
causes a substantial increase in locomotor activity. Rats in a group norm. 
their new environment but soon begin to form clusters in a corner of th 
amphetamine treated rats run their own way in a hurry, while disregi 
other (Fig. 4A). In higher doses (5-10 mg) dexamphetamine causes ster 
haviour as gnawing, spitting and biting, running backwards in their cages 
Social interaction is reduced to a minimum {9, 10).
Merely stereotyped behaviour is seen after a low dose of apomorphint 
grouped male Wistar rats also bizarre social behaviour is observed (Fig. 4
If the level of brain dopamine is increased by injection of Dopa and < 
Dopa decarboxylase inhibitor, this bizarre social interaction together 
stereotyped behaviour is seen already after a low dose of dexamphetamir;
In reserpinized animals the levels of all monoamines are decreased b 
thesis of dopamine which mainly occurs outside the synaptic vesicles is n< 
This means that the synthesis of dopamine continues under the influence 
but that synthesis of noradrenaline is retarded because noradrenaline is 
inside the synaptic vesicles and the vesicles are not able to store amines 
This implies that under the influence of reserpine thè involvement of dopam 
tuated, while the involvement of noradrenaline is evidently reduced. As a c 
amphetamine may liberate or release dopamine in reserpinized animals 
lease may be the cause of the stereotyped behaviour and abnormal s<
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Fig. 4. Effects of amphetamine on behaviour in rats. In each case 4 rats were treated, while 2 served 
as Controls (c). A : dexamphetamine (5,62 /^mol/kg =  1 mg/kg of sulphate) 30 min. after i.p. injection. 
The in jec ted  rats are very active a n d  ru n  a ro u n d  o n  their own. The Controls cluster together in  the 
corner of the cage; B : the same rats after apomorphine (3.16 /^mol/kg =  1 mg/kg of the HC1 salt). 
10 min after i.p. injection. Stereotyped movements as g naw ing  and biting is observed. Following
rvf tiaÏcp fKo ro tc  rn n  orroinct A thpr w lipn tlipx' m p pt TKa
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Fig. 5. Social behaviour of groups of 6 rats (4 treated +  2 C ontrols, c). A : injected with 
(3.16 //mol/kg =  2 mg/kg) followed 12 h later by a-methyl-paratyrosine i.p. (562 fxm 
mg/kg). The injected rats are practically inactive 2 h after aMPT and they remain t 
cluster; B: the same animals injected with dexamphetamine i.p. (5.62 /^mol/kg =  1 r. 
sulphate) 3 h after aMPT. Dexamphetamine is without any effect under the condition 
of catecholamines. On the other hand dexamphetamine induces stereotyped behaviour a
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This implies that amphetamine with respect to the components of action that are 
still predominant after reserpine treatment (as stereotyped behaviour) are due mainly 
to the involvement of dopamine. Since amphetamine may also release other mono- 
amines in the brain under normal circumstances the central efïects may be a com- 
bination of the results of the release of all three monoamines. Reserpine does not 
have the same quantitative effect on the various monoamines in the brain with respect 
to their levels and turnover rate. It is therefore understandable that the various com­
ponents in the action of amphetamine in reserpinized animals are changed to a differ­
ent extent. If animals are pretreated with a-methyl-paratyrosine and thereafter in- 
jected with reserpine, brain levels of noradrenaline and dopamine are reduced to a 
very large extent. In this condition the action of all components of amphetamine 
are blocked.
A
Fig. 6. Social behaviour in groups of 6 male rats (4 treated +  2 Controls, c). A : rats pretreated 
with reserpine and aMPT as in Fig. 3A were given a low dose of the peripheral Dopa decarboxylase 
inhibitor RO-4-4602 i.p. (100 /imol/kg =  29 mg/kg) and Dopa i.p. (31.6 («mol/kg =  6.4 mg/kg).
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The stereotyped behaviour and abnormal social interaction of dexampht 
be restored, however, if these animals are injected with a low dose of Dop; 
of Dopa does not change the behaviour of animals. They appear to t 
reserpinized state (Fig. 6A). If, however, now amphetamine is injected the 
behaviour and social interaction is observed again (Fig. 6B). These experii 
point to the strong involvement of dopamine in the action of amphetamii 
peet to these two components in its action. It must, however, be realized 
condition serotonin levels are decreased substantially as well as noradren; 
So the effects seen under these circumstances after injection of amphetam 
due not only to the involvement of dopamine alone, but also of a lack c 
neurotransmitters. A further indication of the importance of a balance t  
various monoamines of the other neurotransmitters is the finding that 1
Mg/S brain content 
2.0 0 -
1.60-
1.2 0 -
QÖO-
0.40-
treatment-. Ro 4 -4 6 0 2  17fl>umol/kg' i.'- 
DOPA 316/im ol /  kg- i
Dopam ine
0 20 40 60 
time (min)
M$/S bra'n content 
1.60
1.20
0.60
040
N o rad ren alin e
0 20 40 60 
time (min)
/*§/§ brain content
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injected in rats pretreated with a Dopa-decarboxylase inhibitor exhibits a strong 
abnormal social interaction and stereotyped behaviour (5). In these rats, brain 
dopamine levels are increased and this increase is paralleled by a decrease in brain 
serotonin levels, whereas noradrenaline levels remain constant (Fig. 7). On the other 
hand, if Dopa is combined with a monoamine oxydase inhibitor quite different 
effects are observed. Under these circurastances stereotyped behaviour is practically 
absent but the rats are excited. Following Dopa and a MAO-inhibitor, dopamine 
levels are increased also, but at the same time serotonin levels are increased con- 
siderably (Fig. 8).
It has been shown that amphetamine facilitates self-stimulation in rats with elec- 
trodes in the reward areas in the hypothalamus and mid-brain areas (12). This facili- 
tary effect of amphetamine can be suppressed by disulfiram, a drug that inhibitsthe 
conversion of dopamine into noradrenaline. Reversal of this suppression occurred 
with intraventricular injection of noradrenaline, but not if dopamine was given instead 
(21). So also noradrenaline certainly fulfills a role in certain components of the 
action of amphetamine. Whether under normal circumstances also the release of 
serotonin is of importance for the overall action of amphetamine is probable but 
not yet certain. It must again be stressed that changes in the relative role of the mono- 
amines both in the various levels and turnover rates of the free monoamines to a large 
extent determine the various components in the action of amphetamine. For instance 
increase of dopamine and decrease of noradrenaline may result in stereotyped be­
haviour, while an increase of dopamine and an increase in serotonin and noradrenaline 
may cause for example locomotor activity, while an increase of both noradrenaline 
and dopamine may change motivation. The use of selective amphetamine-like 
compounds which have one or only a few of the various components of the ampheta­
mine action present, as well as the use of selective depletors of brain monoamines 
and drugs that selectively increase either the level and or turnover rate of these amines 
may be of great help in elucidating the action of amphetamine and its derivatives. 
Also the use of selective antagonists of neurotransmitters may be of great advantage. 
There is reasonable evidence that neuroleptic drugs block certain effects of amphet­
amine by inhibiting dopamine at the level of its receptors (14).
A drug that has certain components of the action of amphetamine but lacks others, 
is apomorphine. Apomorphine mainly increases stereotyped and abnormal social 
behaviour, but hardly increases locomotor activity in rats and other animals. It must 
be realized that apomorphine in humans causes vomiting probably by involve- 
ment of dopamine receptors in the area postrema. The interesting aspect in this regard 
is the finding that neuroleptic drugs which very effectively block dopamine and so 
completely antagonize the stereotyped behaviour and abnormal social behaviour of
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is mainly found in the nigro-striatal system, noradrenaline especially in the hypo- 
thalamus and serotonin in the midbrain raphe nuclei. It is not at all certain that amines 
found in the largest amounts in certain areas would fulfill their most important role 
in that area. It may therefore be true that monoamines which are found only to a 
small extent in a particular area may be of great importance for the action of for 
instance amphetamine. In the light of the foregoing discussion it is likely that amphet­
amine has a multiple action, therefore may act in different parts of the brain and in 
the various parts in different ways.
Since dopamine is found in the caudate nucleus and other areas mainly, it is 
interesting to note that with injection of dopamine directly into the caudate nucleus, 
the same effects can be induced as with the injection of amphetamine in those areas. 
The effects in this case are mainly stereotyped behaviour but of a restricted type, be- 
cause of the fact that while injection of such a substance in minute amounts in the 
caudate nucleus only a small part of that area is reached (3).
Studies of the locus of action of amphetamine derivatives which are more restricted 
in their components of action in combination with drugs that directly interfere with 
brain monoamines metabolism may be used for a further elucidation of the mecha- 
nism of action and the locus of action of amphetamine and other psychomotor sti­
mulant drugs in the central nervous system. As practical consequence from such 
studies, selective compounds may be found that preferentially may be used in the treat- 
ment of narcolepsia or for hyperkinetic children without producing euphoria and 
addiction. As pointed out in the beginning of this paper not only the mechanism of 
action, but also the locus of action has to be taken into account in designing better 
drugs of this class. In addition the pharmacokinetics or rate processes governing 
absorption distribution and elimination, should be studied in order to design an 
optimal amphetamine-like drug which can be used for the correct medical indication.
SUMMARY
A review of the psychopharmacology of amphetamine-like compounds has been 
given with emphasis on:
(1) Different components in the central stimulant action of amphetamine and 
derivatives.
(2) Structure-activity relationships taking into account differences in the relative 
contribution of the various components of the central stimulant action as well as 
differences in pharmacokinetic parameters.
(3) The significance of the various brain monoamines in the various components 
of central stimulant action.
f4) The locus of action of amphetamines in the brain.
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